Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents.

Recently, selective and systemically active antagonists for the metabotropic glutamate 5 receptor (mGlu(5)) were discovered, and the most potent derivative was found to be MPEP (2-methyl-6-(phenylethynyl)pyridine). Given the high expression of mGlu(5) receptors in limbic forebrain regions, it was decided to evaluate the anxiolytic potential of MPEP. After an acute oral administration, MPEP attenuated the anxiety-dependent variable in a variety of well established anxiety test paradigms. In rats, MPEP (10, 30, and 100 mg/kg) increased punished responses in the Geller-Seifter test, but none of these effects reached statistical significance. MPEP significantly increased the ratio (open/total arm entries; 0.1, 1, and 10 mg/kg), the number of open arm entries (0.1, 1, and 10 mg/kg), as well as time spent on open arm (0.1 and 1 mg/kg) in the elevated plus maze test. Furthermore, MPEP (0.3 and 1 mg/kg) significantly increased the time spent in social contact in the social exploration test. In mice, MPEP attenuated stress-induced hyperthermia (15 and 30 mg/kg) and decreased the number of buried marbles in the marble burying test (7.5 and 30 mg/kg). Finally, MPEP (0.01, 0.1, 1, 10, and 100 mg/kg) was tested on spontaneous locomotor activity in mice, and only a dose of 100 mg/kg significantly reduced vertical activity; no effect was seen on horizontal activity. MPEP (7.5, 15, and 30 mg/kg) was ineffective on d-amphetamine-induced (2.5 mg/kg) locomotor activity in mice and prepulse inhibition in rats (1, 3, or 10 mg/kg). Thus, these findings indicate that MPEP exhibits anxiolytic-like effects and low risks for sedation and psychotomimetic side-effects in rodents.

[1]  W. Spooren,et al.  Effects of the prototypical mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats. , 2000, European journal of pharmacology.

[2]  T. Knöpfel,et al.  Metabotropic glutamate receptors: novel targets for drug development. , 1995, Journal of medicinal chemistry.

[3]  Shigetada Nakanishi,et al.  Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain , 1993, Neuroscience Letters.

[4]  F. Nicoletti,et al.  Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? , 1996, Trends in Neurosciences.

[5]  D. Justesen,et al.  Endogenous hyperthermia in normal human subjects: experimental study of emotional states (II). , 1985, International journal of psychosomatics : official publication of the International Psychosomatics Institute.

[6]  J. Pin,et al.  Pharmacology and functions of metabotropic glutamate receptors. , 1997, Annual review of pharmacology and toxicology.

[7]  A. N. van den Pol,et al.  Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain , 1995, The Journal of comparative neurology.

[8]  Patrick L. McGeer,et al.  Molecular Neurobiology of the Mammalian Brain , 1978, Springer US.

[9]  R. Rodgers,et al.  Anxiety, defence and the elevated plus-maze , 1997, Neuroscience & Biobehavioral Reviews.

[10]  P. Pauwels,et al.  F 11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential. , 1998, The Journal of pharmacology and experimental therapeutics.

[11]  M. Chesselet,et al.  Basal ganglia and movement disorders: an update , 1996, Trends in Neurosciences.

[12]  A. Reeve,et al.  mGlu5 receptors and nociceptive function II. mGlu5 receptors functionally expressed on peripheral sensory neurones mediate inflammatory hyperalgesia , 2001, Neuropharmacology.

[13]  Roland Heckendorn,et al.  2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist , 1999, Neuropharmacology.

[14]  B. Olivier,et al.  5-HT3 receptor antagonists and anxiety; a preclinical and clinical review , 2000, European Neuropsychopharmacology.

[15]  D. Standaert,et al.  Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[16]  J. Penney,et al.  The functional anatomy of basal ganglia disorders , 1989, Trends in Neurosciences.

[17]  C. Parsons,et al.  Glutamate in CNS disorders as a target for drug development: an update. , 1998, Drug news & perspectives.

[18]  F. Gasparini,et al.  SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. , 1999, The Journal of pharmacology and experimental therapeutics.

[19]  W. Soudijn,et al.  5-HT receptor antagonists and anxiety ; a preclinical and clinical review , 2000 .

[20]  R. Rodgers Animal models of 'anxiety': where next? , 1997, Behavioural pharmacology.

[21]  C. Broekkamp,et al.  Major tranquillizers can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim-induced grooming in mice. , 1986, European journal of pharmacology.

[22]  George R. Breese,et al.  Neuroanatomical characterization of Fos induction in rat behavioral models of anxiety , 1996, Brain Research.

[23]  C. Cotman,et al.  The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. , 1989, Annual review of pharmacology and toxicology.

[24]  R. Duvoisin,et al.  The metabotropic glutamate receptors: Structure and functions , 1995, Neuropharmacology.